https://www.selleckchem.com/pr....oducts/elenbecestat.
blish therapeutic efficacy. Recently, a phase III CROWN trial compared the efficacy of two anaplastic lymphoma kinase (ALK) inhibitors and demonstrated that lorlatinib displayed clinical improvement over crizotinib for advanced non-small cell lung cancer (NSCLC) patients. Therefore, the aim of this study was to estimate the cost-effectiveness of lorlatinib as a first-line therapy for patients with advanced ALK-positive (+) NSCLC. A cost-effectiveness analysis was performed using a microsimulation model from the US payer perspective
Like
Comment
Share
